Skip to nav Skip to content
Brian  Czerniecki

Brian Czerniecki, MD, PhD

Department Chair, Breast Oncology
Program Lead, Breast Oncology
Chair, Department of Breast Oncology
4.8 (170)

Specialty: Surgery

Program: Breast Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Breast Cancer, Ductal Carcinoma In Situ, Inflammatory Breast Cancer, Invasive Ductal Carcinoma, Triple Negative Breast Cancer

    Dr. Brian Czerniecki is Chair and Senior Member in the Moffitt Cancer Center Department of Breast Oncology. Dr. Czerniecki received his BS in Biochemistry from the University of Maine and his MD from the University of Medicine and Dentistry of New Jersey (UMDNJ), Robert Wood Johnson Medical School, and his PhD from UMDNJ-Robert Wood Johnson and Rutgers University. Dr. Czerniecki completed his general surgical residency at The Ohio State University and was Surgical Oncology Fellow at the NCI with Dr. Steven Rosenberg prior to his position at the University of Pennsylvania, Philadelphia. While at the University of Pennsylvania, Dr. Czerniecki served as Professor of Surgery, Perelman School of Medicine; Attending Surgeon, Department of Surgery, Hospital of the University of Pennsylvania; and Co-Director of the Rena Rowan Breast Center–Recruitment and Center Expansion. His research interests focus on dendritic cell biology and interactions with T cells. He has developed dendritic cell vaccines for the treatment of cancer. He is involved with several clinical trials for treating patients with early breast cancer with dendritic cell vaccines. Dr. Czerniecki’s research goal is the development of vaccines for the prevention of breast and other solid-tumor cancers. Toward that end, he is working on identifying molecular targets in early breast cancer that can be used to prevent invasion and metastasis. Dr. Czerniecki has more than 100 publications and is recognized nationally for his contribution to the development of sentinel lymph node mapping, a procedure for determining the spread of cancer into lymph nodes that is less invasive than diagnostic surgery.  

    Education & Training

    Board Certification:

    • Surgery - General Surgery


    • National Cancer Institute - Surgical Oncology


    • Ohio State University Hospital - General Surgery

    Medical School:

    • University of Medicine and Dentistry of New Jersey - MD
  • Participating Trials

    Clinical Trial 21452
    Evaluating Gut Microbiome As A Biomarker Of Pathological Complete Response In Patients With Early Triple Negative Breast Cancer - A Pilot Study (TCC)
    Condition: Breast
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Anwar A, Lepore C, Czerniecki BJ, Koski GK, Showalter LE. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy. Cell Immunol. 2024 Mar.397-398:104805. Pubmedid: 38244265.
    • Gautam N, Ramamoorthi G, Champion N, Han HS, Czerniecki BJ. Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development. Mol Aspects Med. 2024 Feb.95:101239. Pubmedid: 38150884.
    • Mistretta B, Rankothgedera S, Castillo M, Rao M, Holloway K, Bhardwaj A, El Noafal M, Albarracin C, El-Zein R, Rezaei H, Su X, Akbani R, Shao XM, Czerniecki BJ, Karchin R, Bedrosian I, Gunaratne PH. Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer. Front Immunol. 2023 Sep.14:1188831. Pubmedid: 37744342. Pmcid: PMC10512078.
    • Jonczyk MM, Karamchandani M, Zaccardelli A, Bahadur A, Fisher CS, Czerniecki B, Margenthaler JA, Persing S, Homsy C, Nardello S, O'Brien J, Losken A, Chatterjee A. External Validation of the Breast Cancer Surgery Risk Calculator (BCSRc): A Predictive Model for Postoperative Complications. Ann Surg Oncol. 2023 Oct.30(10):6245-6253. Pubmedid: 37458950.
    • Jonczyk MM, Karamchandani M, Zaccardelli A, Bahadur A, Fisher CS, Czerniecki B, Margenthaler JA, Persing S, Homsy C, Nardello S, O'Brien J, Losken A, Chatterjee A. ASO Visual Abstract: External Validation of the Breast Cancer Surgery Risk Calculator (BCSRc): A Predictive Model for Postoperative Complications. Ann Surg Oncol. 2023 Oct.30(10):6254-6255. Pubmedid: 37523117.
    • Champion NT, Mooney B, Kim Y, Whiting J, Sun W, Kiluk J, Czerniecki B, Hoover S, Lee MC. Surgeon and Radiologist Evaluation of Electromagnetic Chip Localization for Benign and Malignant Breast Lesions. Ann Surg Oncol. 2023 Nov.30(12):7081-7090. Pubmedid: 37552349.
    • Bari S, Li J, Kang D, Jameel Z, Czerniecki BJ, Costa RLB. A Real-World Data Retrospective Cohort Study of HER2-positive, Early-Stage Breast Cancer in Patients 70 Years of Age or Older: Natural History, Treatment Patterns, and Outcomes. Clin Breast Cancer. 2023 Jun.23(4):378-387. Pubmedid: 36805387.
    • Liveringhouse CL, Mills MN, Ahmed KA, Washington IR, Lee MC, Khakpour N, Laronga C, Czerniecki B, Soliman H, Weinfurtner RJ, Rosa M, Kim Y, Stringfield O, Abdalah M, Diaz R, Montejo M. Phase 2 Study of Preoperative SABR for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 Jul.116(3):611-616. Pubmedid: 36796498.
    • Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Soyano A, Armaghani A, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Laronga C, Rosa M, Khong H, Czerniecki B. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med. 2023 Feb.29(2):450-457. Pubmedid: 36759673.
    • Elleson KM, Englander K, Gallagher J, Chintapally N, Sun W, Whiting J, Mallory M, Kiluk J, Hoover S, Khakpour N, Czerniecki B, Laronga C, Lee MC. Factors Predictive of Positive Lymph Nodes for Breast Cancer. Curr Oncol. 2023 Dec.30(12):10351-10362. Pubmedid: 38132388. Pmcid: PMC10742655.
    • Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Soyano A, Armaghani A, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Laronga C, Rosa M, Khong H, Czerniecki B. Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med. 2023 Dec.29(12):3270. Pubmedid: 36932246.
    • Champion NT, Mooney B, Kim Y, Whiting J, Sun W, Kiluk J, Czerniecki B, Hoover S, Lee MC. ASO Visual Abstract: Surgeon and Radiologist Evaluation of Electromagnetic Chip Localization for Benign and Malignant Breast Lesions. Ann Surg Oncol. 2023 Dec.30(13):8478. Pubmedid: 37679539.
    • Mandula JK, Chang S, Mohamed E, Jimenez R, Sierra-Mondragon RA, Chang DC, Obermayer AN, Moran-Segura CM, Das S, Vazquez-Martinez JA, Prieto K, Chen A, Smalley KSM, Czerniecki B, Forsyth P, Koya RC, Ruffell B, Cubillos-Ruiz JR, Munn DH, Shaw TI, Conejo-Garcia JR, Rodriguez PC. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. Cancer Cell. 2022 Oct.40(10):1145-1160.e9. Pubmedid: 36150390. Pmcid: PMC9561067.
    • Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Oct.24(10):1673-1686. Pubmedid: 35213727. Pmcid: PMC9527526.
    • Gallen C, Dukes CW, Aldrich A, Macaisa L, Mo Q, Cubitt CL, Pilon-Thomas S, Giuliano AR, Czerniecki BJ, Costa RLB. Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. Vaccines (Basel). 2022 Nov.10(11). Pubmedid: 36423026. Pmcid: PMC9696551.
    • Weinfurtner RJ, Abdalah M, Stringfield O, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Latifi K, Niell B, Montejo M, Raghunand N. Quantitative Changes in Intratumoral Habitats on MRI Correlate With Pathologic Response in Early-stage ER/PR+ HER2− Breast Cancer Treated With Preoperative Stereotactic Ablative Body Radiotherapy. J Breast Imaging. 2022 May.4(3):273-284. Pubmedid: 36686407. Pmcid: PMC9851176.
    • Ramamoorthi G, Kodumudi K, Snyder C, Grover P, Zhang H, Greene MI, Basu A, Gallen C, Wiener D, Costa RLB, Han HS, Koski G, Czerniecki BJ. Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma. J Immunother Cancer. 2022 Jun.10(6). Pubmedid: 35710296. Pmcid: PMC9204433.
    • Gautam N, Elleson KM, Ramamoorthi G, Czerniecki BJ. Current State of Cell Therapies for Breast Cancer. Cancer J. 2022 Jul.28(4):301-309. Pubmedid: 35880940. Pmcid: PMC9336570.
    • Basu A, Albert GK, Awshah S, Datta J, Kodumudi KN, Gallen C, Beyer A, Smalley KSM, Rodriguez PC, Dukett DR, Forsyth PA, Soyano A, Koski GK, Lima Barros Costa R, Han H, Soliman H, Lee MC, Kalinski P, Czerniecki BJ. Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine. Cancer Immunol Res. 2022 Jan.10(1):108-125. Pubmedid: 34785506. Pmcid: PMC9414303.
    • Ramamoorthi G, Kodumudi K, Gallen C, Zachariah NN, Basu A, Albert G, Beyer A, Snyder C, Wiener D, Costa RLB, Czerniecki BJ. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. Semin Cancer Biol. 2022 Jan.78:78-89. Pubmedid: 33626407.
    • Mills MN, Potluri TK, Kawahara Y, Fahey M, Figura NB, Soyano AE, Washington IR, Diaz R, Oliver DE, Yu HM, Etame AB, Vogelbaum MA, Czerniecki BJ, Arrington JA, Sahebjam S, Forsyth PA, Soliman HH, Han HS, Ahmed KA. The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs. Breast Cancer Res Treat. 2022 Jan.191(1):209-217. Pubmedid: 34669082.
    • Weinfurtner RJ, Raghunand N, Stringfield O, Abdalah M, Niell BL, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Montejo M. MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. Clin Breast Cancer. 2022 Feb.22(2):e214-e223. Pubmedid: 34384695.
    • Selfridge JM, Sinner HF, Whiting J, Sun W, Mallory MA, Hoover SJ, Kiluk JV, Khakpour N, Czerniecki BJ, Laronga C, Mo Q, Lee MC. Effect of Microporous Polysaccharide Particles in Patients Undergoing Mastectomy. Clin Breast Cancer. 2022 Dec.22(8):e922-e927. Pubmedid: 36055918.
    • Bari S, Boulware D, Li J, Loftus L, Soyano Muller A, Jameel Z, Khong H, Czerniecki BJ, Costa RLB. A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes. Breast Cancer (Dove Med Press). 2022 Aug.14:199-210. Pubmedid: 35967746. Pmcid: PMC9365325.
    • Mills MN, King W, Soyano A, Pina Y, Czerniecki BJ, Forsyth PA, Soliman H, Han HS, Ahmed KA. Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease. J Neurooncol. 2022 Apr.157(2):249-269. Pubmedid: 35244835.
    • Ahmed KA, Kim Y, Arrington JA, Kim S, DeJesus M, Soyano AE, Armaghani AJ, Costa RLB, Khong HT, Loftus LS, Rosa M, Caudell JJ, Diaz R, Robinson TJ, Etame AB, Tran ND, Sahebjam S, Soliman HH, Czerniecki BJ, Forsyth PA, Yu HM, Han HS. Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study. Adv Radiat Oncol. 2021 Sep.6(6):100798. Pubmedid: 34934864. Pmcid: PMC8655428.
    • Jonczyk MM, Fisher CS, Babbitt R, Paulus JK, Freund KM, Czerniecki B, Margenthaler JA, Losken A, Chatterjee A. Surgical Predictive Model for Breast Cancer Patients Assessing Acute Postoperative Complications: The Breast Cancer Surgery Risk Calculator. Ann Surg Oncol. 2021 Sep.28(9):5121-5131. Pubmedid: 33616770. Pmcid: PMC8355048.
    • Showalter LE, Czerniecki BJ, Kodumudi K, Koski GK. Murine Dendritic Cells Grown in Serum-Free Culture Show Potent Therapeutic Activity when Loaded with Novel Th Epitopes in an Orthotopic Model of HER2pos Breast Cancer. Vaccines (Basel). 2021 Sep.9(9). Pubmedid: 34579275. Pmcid: PMC8473293.
    • Sun J, Zhong X, Ma J, Sun W, Han HS, Soliman HH, Loftus LS, Costa RLB, Armaghani AJ, Soyano-Muller AE, Czerniecki BJ, Lee MC, Kiluk JV, Khakpour N, Hoover SJ, Laronga C, Khong HT. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. Cancer Med. 2021 Nov.10(21):7665-7672. Pubmedid: 34590788. Pmcid: PMC8559460.
    • Zachariah NN, Basu A, Gautam N, Ramamoorthi G, Kodumudi KN, Kumar NB, Loftus L, Czerniecki BJ. Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination. Front Immunol. 2021 Nov.12:786286. Pubmedid: 34899753. Pmcid: PMC8652247.
    • Mills MN, Naz A, Thawani C, Walker C, Figura NB, Kushchayev S, Oliver DE, Etame AB, Yu HM, Robinson TJ, Liu JKC, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases. BMC Cancer. 2021 May.21(1):552. Pubmedid: 33992087. Pmcid: PMC8126143.
    • Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett D, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM. Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunol Res. 2021 May.9(5):554-567. Pubmedid: 33653716. Pmcid: PMC8102376.
    • Mills MN, Thawani C, Figura NB, Oliver DE, Soyano AE, Etame A, Robinson TJ, Liu JK, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Yu HM, Ahmed KA. Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. J Neurooncol. 2021 May.152(3):591-601. Pubmedid: 33742358.
    • Basu A, Ramamoorthi G, Albert G, Gallen C, Beyer A, Snyder C, Koski G, Disis ML, Czerniecki BJ, Kodumudi K. Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy. Front Immunol. 2021 May.12:669474. Pubmedid: 34012451. Pmcid: PMC8126720.
    • Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, Etame A, Yu HM, Robinson TJ, Liu J, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021 Mar.21(1):223. Pubmedid: 33663447. Pmcid: PMC7934378.
    • Artzy-Randrup Y, Epstein T, Brown JS, Costa RLB, Czerniecki BJ, Gatenby RA. Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy. NPJ Breast Cancer. 2021 Mar.7(1):26. Pubmedid: 33707440. Pmcid: PMC7952601.
    • Sun J, Henry DA, Carr MJ, Yazdankhahkenary A, Laronga C, Lee MC, Hoover SJ, Sun W, Czerniecki BJ, Khakpour N, Kiluk JV. Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization. Clin Breast Cancer. 2021 Jun.21(3):e189-e193. Pubmedid: 32893094.
    • Law V, Baldwin M, Ramamoorthi G, Kodumudi K, Tran N, Smalley I, Duckett D, Kalinski P, Czerniecki B, Smalley KSM, Forsyth PA. A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease. J Vis Exp. 2021 Jan.(167). Pubmedid: 33586709. Pmcid: PMC9014476.
    • Soliman H, Hogue D, Han HS, Mooney B, Lima Barros Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Rosa M, Khong H, Czerniecki BJ. A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 Feb.27(4):1012-1018. Pubmedid: 33219014.
    • Jia Y, Kodumudi KN, Ramamoorthi G, Basu A, Snyder C, Wiener D, Pilon-Thomas S, Grover P, Zhang H, Greene MI, Mo Q, Tong Z, Chen YZ, Costa RLB, Han H, Lee C, Soliman H, Conejo-Garcia JR, Koski G, Czerniecki BJ. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Mol Ther. 2021 Apr.29(4):1541-1556. Pubmedid: 33412308. Pmcid: PMC8058490.
    • Ghimirey N, Steele C, Czerniecki BJ, Koski GK, Showalter LE. Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2pos Breast Cancer. Int J Breast Cancer. 2021 Apr.2021:8818393. Pubmedid: 33936816. Pmcid: PMC8062178.
    • Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer. 2020 Mar.6:10. Pubmedid: 32195333. Pmcid: PMC7067811.
    • Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer. 2020 Mar.6(1):10. Pubmedid: 33574294.
    • Showalter L, Czerniecki BJ, Koski GK. Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo. Oncotarget. 2020 Jul.11(30):2873-2888. Pubmedid: 32774769. Pmcid: PMC7392628.
    • Rajarajan N, Mariotti V, Basu A, Kodumudi K, Han H, Czerniecki B, Hoover S. Strategies to Combat Human Epidermal Growth Factor Receptor 2 (HER2) Resistance in HER2-Positive Breast Cancer. Crit Rev Oncog. 2020 Jul.25(3):209-231. Pubmedid: 33463942.
    • Oechsle CM, Showalter LE, Novak CM, Czerniecki BJ, Koski GK. Statin Drugs Plus Th1 Cytokines Potentiate Apoptosis and Ras Delocalization in Human Breast Cancer Lines and Combine with Dendritic Cell-Based Immunotherapy to Suppress Tumor Growth in a Mouse Model of HER-2pos Disease. Vaccines (Basel). 2020 Feb.8(1). Pubmedid: 32041347. Pmcid: PMC7157728.
    • Burke EE, Laronga C, Sun W, DeBiase S, Naqvi SMH, Fridley B, Czerniecki BJ, Hoover SJ, Khakpour N, Kiluk JV, Lee MC. Implant-sparing Mastectomy: An Alternative for Women Undergoing Mastectomy With Retropectoral Implants. Clin Breast Cancer. 2020 Feb.20(1):e14-e19. Pubmedid: 31780380. Pmcid: PMC7771331.
    • Mills MN, Figura NB, Arrington JA, Yu HM, Etame AB, Vogelbaum MA, Soliman H, Czerniecki BJ, Forsyth PA, Han HS, Ahmed KA. Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Res Treat. 2020 Apr.180(2):279-300. Pubmedid: 32030570.
    • Figura NB, Rizk VT, Armaghani AJ, Arrington JA, Etame AB, Han HS, Czerniecki BJ, Forsyth PA, Ahmed KA. Breast leptomeningeal disease: a review of current practices and updates on management. Breast Cancer Res Treat. 2019 Sep.177(2):277-294. Pubmedid: 31209686.
    • Chatterjee A, Asban A, Jonczyk M, Chen L, Czerniecki B, Fisher CS. A cost-utility analysis comparing large volume displacement oncoplastic surgery to mastectomy with free flap reconstruction in the treatment of breast cancer. Am J Surg. 2019 Sep.218(3):597-604. Pubmedid: 30739739.
    • Namjoshi P, Showalter L, Czerniecki BJ, Koski GK. T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells. Oncotarget. 2019 Oct.10(57):6006-6020. Pubmedid: 31666931. Pmcid: PMC6800266.
    • Lowenfeld L, Xu S, Czerniecki BJ. CD4+ Th1 to the rescue in HER-2+ breast cancer. Oncoimmunology. 2019 May.8(10):e1078062. Pubmedid: 31646065. Pmcid: PMC6791441.
    • Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, Robinson TJ, Etame AB, Tran ND, Liu J, Washington I, Diaz R, Czerniecki BJ, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat. 2019 Jun.175(3):781-788. Pubmedid: 30859348.
    • Basu A, Ramamoorthi G, Jia Y, Faughn J, Wiener D, Awshah S, Kodumudi K, Czerniecki BJ. Immunotherapy in breast cancer: Current status and future directions. Adv Cancer Res. 2019 Jun.143:295-349. Pubmedid: 31202361.
    • Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ. Vaccine Therapies for Breast Cancer. Surg Oncol Clin N Am. 2019 Jul.28(3):353-367. Pubmedid: 31079793.
    • Showalter LE, Oechsle C, Ghimirey N, Steele C, Czerniecki BJ, Koski GK. Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib. PLoS One. 2019 Jan.14(1):e0210209. Pubmedid: 30657766. Pmcid: PMC6338365.
    • Costa R, Zaman S, Sharpe S, Helenowski I, Shaw C, Han H, Soliman H, Czerniecki B. A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer. Drug Des Devel Ther. 2019 Jan.13:309-316. Pubmedid: 30679903. Pmcid: PMC6338114.
    • Ahmed KA, Liveringhouse CL, Mills MN, Figura NB, Grass GD, Washington IR, Harris EE, Czerniecki BJ, Blumencranz PW, Eschrich SA, Scott JG, Diaz R, Torres-Roca JF. Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management. EBioMedicine. 2019 Aug.47:163-169. Pubmedid: 31416721. Pmcid: PMC6796536.
    • Kodumudi KN, Ramamoorthi G, Snyder C, Basu A, Jia Y, Awshah S, Beyer AP, Wiener D, Lam L, Zhang H, Greene MI, Costa RLB, Czerniecki BJ. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. Front Immunol. 2019 Aug.10:1939. Pubmedid: 31475002. Pmcid: PMC6702967.
    • López Alfonso JC, Poleszczuk J, Walker R, Kim S, Pilon-Thomas S, Conejo-Garcia JJ, Soliman H, Czerniecki B, Harrison LB, Enderling H. Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. JCO Clin Cancer Inform. 2019 Apr.3:1-16. Pubmedid: 30964698. Pmcid: PMC6661069.
    • De La Cruz LM, Czerniecki BJ. Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer. Ann Surg Oncol. 2018 Oct.25(10):2852-2857. Pubmedid: 30014455.
    • Rosemblit C, Datta J, Lowenfeld L, Xu S, Basu A, Kodumudi K, Wiener D, Czerniecki BJ. Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies. Oncotarget. 2018 May.9(33):23058-23077. Pubmedid: 29796172. Pmcid: PMC5955413.
    • So A, De La Cruz LM, Williams AD, Bahng J, Liao G, McDonald ES, Fisher CS, Czerniecki BJ, Sataloff D, Tchou J. The impact of preoperative magnetic resonance imaging and lumpectomy cavity shavings on re-excision rate in pure ductal carcinoma in situ-A single institution's experience. J Surg Oncol. 2018 Mar.117(4):558-566. Pubmedid: 29127721.
    • Herbert G, Karakousis GC, Bartlett EK, Zaheer S, Graham D, Czerniecki BJ, Fraker DL, Ariyan C, Coit DG, Brady MS. Transected thin melanoma: Implications for sentinel lymph node staging. J Surg Oncol. 2018 Mar.117(4):567-571. Pubmedid: 29194673. Pmcid: PMC5878707.
    • Ahmed KA, Grass GD, Orman AG, Liveringhouse C, Montejo ME, Soliman HH, Han HS, Czerniecki BJ, Torres-Roca JF, Diaz R. Personalizing Radiation Treatment Delivery in the Management of Breast Cancer. Int J Breast Cancer. 2018 Jun.2018:6729802. Pubmedid: 29984003. Pmcid: PMC6015692.
    • Abbott J, Buckley M, Taylor LA, Xu G, Karakousis G, Czerniecki BJ, Gimotty PA, Zhang PJ. Histological immune response patterns in sentinel lymph nodes involved by metastatic melanoma and prognostic significance. J Cutan Pathol. 2018 Jun.45(6):377-386. Pubmedid: 29446846.
    • Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, Anderson AARA, Czerniecki BJ, Harrison LB, Moros EG, Enderling H. Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy. Sci Rep. 2018 Jun.8(1):9474. Pubmedid: 29930290. Pmcid: PMC6013469.
    • Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018 Apr.10(436). Pubmedid: 29643231.
    • Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun. 2017 Sep.8(1):607. Pubmedid: 28928360. Pmcid: PMC5605714.
    • Mustafa RE, DeStefano LM, Bahng J, Yoon-Flannery K, Fisher CS, Zhang PJ, Tchou J, Czerniecki BJ, De La Cruz LM. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer. Ann Surg Oncol. 2017 Oct.24(10):2999-3003. Pubmedid: 28766212.
    • Costa RLB, Costa-Filho RB, Rosa M, Czerniecki BJ. Occult Breast Carcinoma Presenting as Scalp Metastasis. Case Rep Oncol. 2017 Nov.10(3):992-997. Pubmedid: 29279704. Pmcid: PMC5731106.
    • Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res. 2017 Jun.19(1):75. Pubmedid: 28666457. Pmcid: PMC5493088.
    • Nocera NF, Lee MC, Czerniecki BJ. Boosting anti-HER2 CD4 T-helper responses in HER2 expressing ductal carcinoma in situ. Future Oncol. 2017 Jul.13(17):1459-1462. Pubmedid: 28766964.
    • Fracol M, Datta J, Lowenfeld L, Xu S, Zhang PJ, Fisher CS, Czerniecki BJ. Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes. Ann Surg Oncol. 2017 Feb.24(2):407-417. Pubmedid: 27663569.
    • Sinnamon AJ, Neuwirth MG, Bartlett EK, Zaheer S, Etherington MS, Xu X, Elder DE, Czerniecki BJ, Fraker DL, Karakousis GC. Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma. J Surg Oncol. 2017 Dec.116(7):848-855. Pubmedid: 28650537.
    • Costa RLB, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives. Cancer Treat Rev. 2017 Dec.61:107-115. Pubmedid: 29125981.
    • Karakousis G, Gimotty PA, Bartlett EK, Sim MS, Neuwirth MG, Fraker D, Czerniecki BJ, Faries MB. Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis. Ann Surg Oncol. 2017 Apr.24(4):952-959. Pubmedid: 27807729. Pmcid: PMC5555768.
    • Nocera NF, Lee MC, De La Cruz LM, Rosemblit C, Czerniecki BJ. Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Front Pharmacol. 2016 Oct.7:356. Pubmedid: 27766079. Pmcid: PMC5052279.
    • De La Cruz LM, Nocera NF, Czerniecki BJ. Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential. Immunotherapy. 2016 Oct.8(10):1219-1232. Pubmedid: 27605070. Pmcid: PMC5967360.
    • De La Cruz L, Blankenship SA, Chatterjee A, Geha R, Nocera N, Czerniecki BJ, Tchou J, Fisher CS. Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review. Ann Surg Oncol. 2016 Oct.23(10):3247-3258. Pubmedid: 27357177.
    • Namjoshi P, Showalter L, Czerniecki BJ, Koski GK. T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells. Oncotarget. 2016 Jun. Pubmedid: 27374107.
    • Ban HY, Schweiger M, Kavuri VC, Cochran JM, Xie L, Busch DR, Katrašnik J, Pathak S, Chung SH, Lee K, Choe R, Czerniecki BJ, Arridge SR, Yodh AG. Heterodyne frequency-domain multispectral diffuse optical tomography of breast cancer in the parallel-plane transmission geometry. Med Phys. 2016 Jul.43(7):4383. Pubmedid: 27370153. Pmcid: PMC4920810.
    • Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ. Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer. Oncoimmunology. 2016 Jul.6(9):e1207032. Pubmedid: 28932627. Pmcid: PMC5599079.
    • Pyfer B, Chatterjee A, Chen L, Nigriny J, Czerniecki B, Tchou J, Fisher C. Early Postoperative Outcomes in Breast Conservation Surgery Versus Simple Mastectomy with Implant Reconstruction: A NSQIP Analysis of 11,645 Patients. Ann Surg Oncol. 2016 Jan.23(1):92-98. Pubmedid: 26219243.
    • Datta J, Fracol M, McMillan MT, Berk E, Xu S, Goodman N, Lewis DA, DeMichele A, Czerniecki BJ. Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring. JAMA Oncol. 2016 Feb.2(2):242-246. Pubmedid: 26719971.
    • Cintolo JA, Datta J, Xu S, Gupta M, Somasundaram R, Czerniecki BJ. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma. Melanoma Res. 2016 Feb.26(1):1-11. Pubmedid: 26451873.
    • Ecker BL, Taylor L, Zhang PJ, Furth EE, Ginsberg GG, McMillan MT, Datta J, Czerniecki BJ, Roses RE. HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction. PLoS One. 2016 Aug.11(8):e0161781. Pubmedid: 27559738. Pmcid: PMC4999185.
    • Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Francisco Espinel C, Feldman E, Gallagher K, Greenup R, Herrmann V, Kuerer H, Malik M, Manahan E, O'Neill J, Patel M, Sebastian M, Wheeler A, Kass R. Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer. Ann Surg Oncol. 2015 Oct.22(10):3184-3190. Pubmedid: 26224406.
    • Chatterjee A, Pyfer B, Chen L, Czerniecki B, Tchou J, Fisher C. Resident and Fellow Participation in Breast Surgery: An American College of Surgeons NSQIP Clinical Outcomes Analysis. J Am Coll Surg. 2015 Nov.221(5):988-994. Pubmedid: 26372636.
    • Datta J, Xu S, Rosemblit C, Smith JB, Cintolo JA, Powell DJ, Czerniecki BJ. CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers. Cancer Immunol Res. 2015 May.3(5):455-463. Pubmedid: 25791067. Pmcid: PMC4556111.
    • Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Res. 2015 May.17:71. Pubmedid: 25997452. Pmcid: PMC4488128.
    • Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol. 2015 Jun.6:271. Pubmedid: 26082780. Pmcid: PMC4451636.
    • Datta J, Rosemblit C, Berk E, Showalter L, Namjoshi P, Mick R, Lee KP, Brod AM, Yang RL, Kelz RR, Fitzpatrick E, Hoyt C, Feldman MD, Zhang PJ, Xu S, Koski GK, Czerniecki BJ. Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration. Oncoimmunology. 2015 Apr.4(10):e1022301. Pubmedid: 26451293. Pmcid: PMC4589053.
    • Salasky V, Yang RL, Datta J, Graves HL, Cintolo JA, Meise C, Karakousis GC, Czerniecki BJ, Kelz RR. Racial disparities in the use of outpatient mastectomy. J Surg Res. 2014 Jan.186(1):16-22. Pubmedid: 24054549.
    • Bartlett EK, Gimotty PA, Sinnamon AJ, Wachtel H, Roses RE, Schuchter L, Xu X, Elder DE, Ming M, Elenitsas R, Guerry D, Kelz RR, Czerniecki BJ, Fraker DL, Karakousis GC. Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy. Ann Surg Oncol. 2014 Feb.21(2):643-649. Pubmedid: 24121883. Pmcid: PMC4006195.
    • Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med. 2014 Dec.87(4):491-518. Pubmedid: 25506283. Pmcid: PMC4257036.
    • Roses RE, Datta J, Czerniecki BJ. Radiation as immunomodulator: implications for dendritic cell-based immunotherapy. Radiat Res. 2014 Aug.182(2):211-218. Pubmedid: 24992163. Pmcid: PMC4143901.
    • Bartlett EK, Meise C, Bansal N, Fischer JP, Low DW, Czerniecki BJ, Roses RE, Fraker DL, Kelz RR, Karakousis GC. Sartorius transposition during inguinal lymphadenectomy for melanoma. J Surg Res. 2013 Sep.184(1):209-215. Pubmedid: 23688786.
    • Cintolo JA, Gimotty P, Blair A, Guerry D, Elder DE, Hammond R, Elenitsas R, Xu X, Fraker D, Schuchter LM, Czerniecki BJ, Karakousis G. Local immune response predicts survival in patients with thick (t4) melanomas. Ann Surg Oncol. 2013 Oct.20(11):3610-3617. Pubmedid: 23838911.
    • Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, Fisher C, Tchou J, Fox K, Zhang P, Czerniecki BJ. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS. Ann Surg Oncol. 2013 Oct.20(10):3233-3239. Pubmedid: 23851609.
    • Terhune J, Berk E, Czerniecki BJ. Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy. Vaccines (Basel). 2013 Nov.1(4):527-549. Pubmedid: 26344346. Pmcid: PMC4494209.
    • Yang RL, Kelz RR, Czerniecki BJ. Immediate reconstruction following nipple-sparing mastectomy: one option for young breast cancer patients with early stage disease. J Thorac Dis. 2013 Jun.5(3):200-202. Pubmedid: 23825742. Pmcid: PMC3698276.
    • Yang RL, Newman AS, Lin IC, Reinke CE, Karakousis GC, Czerniecki BJ, Wu LC, Kelz RR. Trends in immediate breast reconstruction across insurance groups after enactment of breast cancer legislation. Cancer. 2013 Jul.119(13):2462-2468. Pubmedid: 23585144.
    • Busch DR, Choe R, Rosen MA, Guo W, Durduran T, Feldman MD, Mies C, Czerniecki BJ, Tchou J, Demichele A, Schnall MD, Yodh AG. Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy. Biomed Opt Express. 2013 Jan.4(1):105-121. Pubmedid: 23304651. Pmcid: PMC3539198.
    • Yang RL, Newman AS, Reinke CE, Lin IC, Karakousis GC, Czerniecki BJ, Wu LC, Kelz RR. Racial disparities in immediate breast reconstruction after mastectomy: impact of state and federal health policy changes. Ann Surg Oncol. 2013 Feb.20(2):399-406. Pubmedid: 23054106.
    • Showalter SL, Grover S, Sharma S, Lin L, Czerniecki BJ. Factors influencing surgical and adjuvant therapy in stage I breast cancer: a SEER 18 database analysis. Ann Surg Oncol. 2013 Apr.20(4):1287-1294. Pubmedid: 23135311.
    • Lee MK, Xu S, Fitzpatrick EH, Sharma A, Graves HL, Czerniecki BJ. Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine. PLoS One. 2013.8(11):e74698. Pubmedid: 24244265. Pmcid: PMC3823870.
    • Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012 Sep.118(17):4354-4362. Pubmedid: 22252842. Pmcid: PMC3330145.
    • Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ. Dendritic cell-based vaccines: barriers and opportunities. Future Oncol. 2012 Oct.8(10):1273-1299. Pubmedid: 23130928. Pmcid: PMC4260651.
    • Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Czerniecki BJ. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother. 2012 Jan.35(1):54-65. Pubmedid: 22130160. Pmcid: PMC3241864.
    • Chiang CL, Hagemann AR, Leskowitz R, Mick R, Garrabrant T, Czerniecki BJ, Kandalaft LE, Powell DJ, Coukos G. Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS One. 2012 Aug.6(12):e28732. Pubmedid: 22194898. Pmcid: PMC3237492.
    • Harada S, Mick R, Roses RE, Graves H, Niu H, Sharma A, Schueller JE, Nisenbaum H, Czerniecki BJ, Zhang PJ. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease. J Surg Oncol. 2011 Oct.104(5):458-465. Pubmedid: 21557226. Pmcid: PMC3168675.
    • Chiang CL, Maier DA, Kandalaft LE, Brennan AL, Lanitis E, Ye Q, Levine BL, Czerniecki BJ, Powell DJ, Coukos G. Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. J Transl Med. 2011 Nov.9:198. Pubmedid: 22082029. Pmcid: PMC3283529.
    • Karakousis GC, Czerniecki BJ. Diagnosis of Melanoma. PET Clin. 2011 Jan.6(1):1-8. Pubmedid: 27156351.
    • Paustian C, Caspell R, Johnson T, Cohen PA, Shu S, Xu S, Czerniecki BJ, Koski GK. Effect of multiple activation stimuli on the generation of Th1-polarizing dendritic cells. Hum Immunol. 2011 Jan.72(1):24-31. Pubmedid: 20951755.
    • Graves H, Czerniecki BJ. Circulating tumor cells in breast cancer patients: an evolving role in patient prognosis and disease progression. Patholog Res Int. 2011 Jan.2011:621090. Pubmedid: 21253472. Pmcid: PMC3022182.
    • Busch DR, Guo W, Choe R, Durduran T, Feldman MD, Mies C, Rosen MA, Schnall MD, Czerniecki BJ, Tchou J, DeMichele A, Putt ME, Yodh AG. Computer aided automatic detection of malignant lesions in diffuse optical mammography. Med Phys. 2010 Apr.37(4):1840-1849. Pubmedid: 20443506. Pmcid: PMC2864673.
    • Bahl S, Roses RE, Sharma A, Koldovsky U, Xu S, Weinstein S, Nisenbaum H, Fox K, Pasha T, Zhang P, Araujo L, Carver J, Czerniecki BJ. Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines. Am J Surg. 2009 Oct.198(4):488-494. Pubmedid: 19800453. Pmcid: PMC2758542.
    • Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ, Czerniecki BJ. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2009 May.18(5):1386-1389. Pubmedid: 19383888. Pmcid: PMC2713817.
    • Roses RE, Kumar R, Alavi A, Czerniecki BJ. The Role of Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Staging of Breast Cancer. PET Clin. 2009 Jul.4(3):265-276. Pubmedid: 27157099.
    • Bahl S, Alavi A, Basu S, Kumar R, Czerniecki BJ. The Role of PET and PET/CT in the Surgical Management of Breast Cancer: A Review. PET Clin. 2009 Jul.4(3):277-287. Pubmedid: 27157100.
    • Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu XY, Wang Z, Zhang WJ, Carter CS, Awad M, Distel CA, Nagem H, Paustian CC, Johnson TD, Tisdale JF, Shu S. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood. 2008 Sep.112(5):1832-1843. Pubmedid: 18577706. Pmcid: PMC2518890.
    • Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ. Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol. 2008 Oct.181(7):5120-5127. Pubmedid: 18802116.
    • Roses RE, Xu M, Koski GK, Czerniecki BJ. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene. 2008 Jan.27(2):200-207. Pubmedid: 18176601.
    • Weinstein SP, Orel SG, Pinnamaneni N, Tchou J, Czerniecki B, Boraas M, Rosato E, Solin LJ. Mammographic appearance of recurrent breast cancer after breast conservation therapy. Acad Radiol. 2008 Feb.15(2):240-244. Pubmedid: 18206623.
    • Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schuchter L, Spitz FR, Czerniecki BJ, Guerry D. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007 Mar.25(9):1129-1134. Pubmedid: 17369575.
    • Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res. 2007 Jul.67(14):6531-6534. Pubmedid: 17638860.
    • Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007 Feb.67(4):1842-1852. Pubmedid: 17293384.
    • Mavi A, Cermik TF, Urhan M, Puskulcu H, Basu S, Yu JQ, Zhuang H, Czerniecki B, Alavi A. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med. 2007 Aug.48(8):1266-1272. Pubmedid: 17631558.
    • Swoboda RK, Somasundaram R, Caputo L, Ochoa EM, Gimotty PA, Marincola FM, Van Belle P, Barth S, Elder D, Guerry D, Czerniecki B, Schuchter L, Vonderheide RH, Herlyn D. Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display. Cancer Res. 2007 Apr.67(8):3555-3559. Pubmedid: 17440064.
    • Kesmodel SB, Canter RJ, Terhune KP, Bauer TW, Mick R, Rosato EF, Spitz FR, Fraker DL, Alavi A, Czerniecki BJ. Use of radiotracer for sentinel lymph node mapping in breast cancer optimizes staging independent of site of administration. Clin Nucl Med. 2006 Sep.31(9):527-533. Pubmedid: 16921275.
    • Mavi A, Urhan M, Yu JQ, Zhuang H, Houseni M, Cermik TF, Thiruvenkatasamy D, Czerniecki B, Schnall M, Alavi A. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006 Sep.47(9):1440-1446. Pubmedid: 16954551.
    • Zhang T, Somasundaram R, Berking C, Caputo L, Van Belle P, Elder D, Czerniecki B, Hotz S, Schuchter L, Spitz FR, Berencsi K, Rani P, Marincola F, Qiu R, Herlyn D. Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells. Cancer Biol Ther. 2006 Oct.5(10):1304-1312. Pubmedid: 16929176.
    • Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P, Hotz S, Elder DE, Marincola FM, Schuchter L, Guerry D, Czerniecki BJ, Herlyn D. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res. 2006 Mar.66(6):3287-3293. Pubmedid: 16540682.
    • Durduran T, Choe R, Yu G, Zhou C, Tchou JC, Czerniecki BJ, Yodh AG. Diffuse optical measurement of blood flow in breast tumors. Opt Lett. 2005 Nov.30(21):2915-2917. Pubmedid: 16279468.
    • Faries MB, Czerniecki BJ. Dendritic cells in melanoma immunotherapy. CURR TREAT OPTION ON. 2005 May.6(3):175-184. Pubmedid: 15869729.
    • Choe R, Corlu A, Lee K, Durduran T, Konecky SD, Grosicka-Koptyra M, Arridge SR, Czerniecki BJ, Fraker DL, DeMichele A, Chance B, Rosen MA, Yodh AG. Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI. Med Phys. 2005 Apr.32(4):1128-1139. Pubmedid: 15895597.
    • Koski GK, Karikó K, Xu S, Weissman D, Cohen PA, Czerniecki BJ. Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol. 2004 Apr.172(7):3989-3993. Pubmedid: 15034009.
    • Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol. 2003 Sep.171(5):2251-2261. Pubmedid: 12928369.
    • Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003 Oct.21(20):3826-3835. Pubmedid: 14551301.
    • Prabakaran I, Menon C, Xu S, Gómez-Yafal A, Czerniecki BJ, Fraker DL. Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells. Ann Surg Oncol. 2002 May.9(4):411-418. Pubmedid: 11986195.
    • Bauer TW, Spitz FR, Callans LS, Alavi A, Mick R, Weinstein SP, Bedrosian I, Fraker DL, Bauer TL, Czerniecki BJ. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol. 2002 Mar.9(2):169-176. Pubmedid: 11888875.
    • Bedrosian I, Schlencker J, Spitz FR, Orel SG, Fraker DL, Callans LS, Schnall M, Reynolds C, Czerniecki BJ. Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions. Ann Surg Oncol. 2002 Jun.9(5):457-461. Pubmedid: 12052756.
    • Faries MB, Bedrosian I, Xu S, Koski G, Roros JG, Moise MA, Nguyen HQ, Engels FH, Cohen PA, Czerniecki BJ. Calcium signaling inhibits interleukin-12 production and activates CD83(+) dendritic cells that induce Th2 cell development. Blood. 2001 Oct.98(8):2489-2497. Pubmedid: 11588047.
    • Wildemore JK, Schuchter L, Mick R, Synnestvedt M, Elenitsas R, Bedrosian I, Czerniecki BJ, Guerry D, Lessin SR, Elder DE, Bucky LP. Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study. Ann Plast Surg. 2001 May.46(5):488-494. Pubmedid: 11352421.
    • Chang JH, Vines E, Bertsch H, Fraker DL, Czerniecki BJ, Rosato EF, Lawton T, Conant EF, Orel SG, Schuchter L, Fox KR, Zieber N, Glick JH, Solin LJ. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer. 2001 Apr.91(7):1231-1237. Pubmedid: 11283921.
    • Czerniecki BJ, Bedrosian I, Faries M, Alavi A. Revolutionary impact of lymphoscintigraphy and intraoperative sentinel node mapping in the clinical practice of oncology. Semin Nucl Med. 2001 Apr.31(2):158-164. Pubmedid: 11330786.
    • Engels FH, Kreisel D, Faries MB, Bedrosian I, Koski GK, Cohen PA, Czerniecki BJ. Calcium ionophore activation of chronic myelogenous leukemia progenitor cells into dendritic cells is mediated by calcineurin phosphatase. Leuk Res. 2000 Oct.24(10):795-804. Pubmedid: 10996197.
    • Bedrosian I, Faries MB, Guerry D, Elenitsas R, Schuchter L, Mick R, Spitz FR, Bucky LP, Alavi A, Elder DE, Fraker DL, Czerniecki BJ. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol. 2000 May.7(4):262-267. Pubmedid: 10819365.
    • Bedrosian I, Roros JG, Xu S, Nguyen HQ, Engels F, Faries MB, Koski GK, Cohen PA, Czerniecki BJ. Granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-12 synergize with calcium ionophore to enhance dendritic cell function. J Immunother. 2000 May.23(3):311-320. Pubmedid: 10838660.
    • Faries MB, Bedrosian I, Reynolds C, Nguyen HQ, Alavi A, Czerniecki BJ. Active macromolecule uptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status. Ann Surg Oncol. 2000 Mar.7(2):98-105. Pubmedid: 10761787.
    • Bedrosian I, Reynolds C, Mick R, Callans LS, Grant CS, Donohue JH, Farley DR, Heller R, Conant E, Orel SG, Lawton T, Fraker DL, Czerniecki BJ. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000 Jun.88(11):2540-2545. Pubmedid: 10861431.
    • Engels FH, Koski GK, Bedrosian I, Xu S, Luger S, Nowell PC, Cohen PA, Czerniecki BJ. Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. Proc Natl Acad Sci U S A. 1999 Aug.96(18):10332-10337. Pubmedid: 10468608. Pmcid: PMC17888.
    • Czerniecki BJ, Carter C, Rivoltini L, Koski GK, Kim HI, Weng DE, Roros JG, Hijazi YM, Xu S, Rosenberg SA, Cohen PA. Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol. 1997 Oct.159(8):3823-3837. Pubmedid: 9378970.
    • Czerniecki BJ, Witz G. Arachidonic acid potentiates superoxide anion radical production by murine peritoneal macrophages stimulated with tumor promoters. Carcinogenesis. 1989 Oct.10(10):1769-1775. Pubmedid: 2551522.
    • Czerniecki BJ, Witz G. Tumor promoters stimulate the formation of 1,2-diacylglycerol in murine peritoneal macrophages: a possible mechanism for stimulating superoxide anion radical production. Cancer Lett. 1989 Nov.48(1):29-36. Pubmedid: 2555042.
    • Witz G, Czerniecki BJ. Tumor promoters differ in their ability to stimulate superoxide anion radical production by murine peritoneal exudate cells following in vivo administration. Carcinogenesis. 1989 May.10(5):807-811. Pubmedid: 2539913.
    • Chatterjee A, Serniak N, Czerniecki BJ. Sentinel lymph node biopsy in breast cancer: a work in progress. Cancer J. 21(1):7-10. Pubmedid: 25611773. Pmcid: PMC4304410.
    • Chatterjee A, Dayicioglu D, Khakpour N, Czerniecki BJ. Oncoplastic Surgery: Keeping It Simple With 5 Essential Volume Displacement Techniques for Breast Conservation in a Patient With Moderate- to Large-Sized Breasts. Cancer Control. 24(4):1073274817729043. Pubmedid: 28975837. Pmcid: PMC5937235.
  • Grants

    Title: Research Plan 7: Expansion, Enrichment, and Confirmation of Neoantigen Reactive TIL fromBreast Tumors
    Sponsor: Turnstone Biologics
    PI: Czerniecki, B.
    Title: Overcoming Resistance in HER2 Breast Cancer through a Novel Immunotherapy Approach
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI: Czerniecki, B.
    Title: Correcting the Anti-HER-2 CD4 Th1 Response in Breast Cancer Therapy to Prevent Recurrence
    Sponsor: US Army
    PI: Czerniecki, B., CO-PI: Soliman, H.
    Title: Novel Immunotherapy for Brain-Metastatic Breast Cancer
    Sponsor: US Army
    PI: Czerniecki, B.
  • Patient Comments

    Overall Satisfaction


    170 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor